PALI — PALISADE BIO, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1357459 ·
Last close
$1.78
Market Cap
$308.97M
52W High
$2.86
52W Low
$1.48
ADV30
2,724,694
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,748,000 | -9,600,000 | 133,315,000 | 132,628,000 | 5,953,000 |
| Dec 2025 | 0 | — | -9,981,000 | -8,899,000 | 134,344,000 | 133,385,000 | 4,964,000 |
| Sep 2025 | 0 | — | -2,922,000 | -2,868,000 | 6,973,000 | 5,227,000 | 3,761,000 |
| Jun 2025 | 0 | — | -2,843,000 | -2,784,000 | 6,667,000 | 5,417,000 | 4,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,404,000
Investing CF
$0
Financing CF
$137,831,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.48
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-162,325,000
Inventory
—
Receivables
$9,000
ST Investments
—
EBIT TTM
$-24,141,000
Pretax Income TTM
$-24,151,000
Interest Exp TTM
$10,000
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -18,056,000 | -16,781,000 | 134,344,000 | 4,964,000 | — | -10,847,000 |
| Dec 2024 | 0 | -14,859,000 | -14,438,000 | 10,880,000 | 3,388,000 | — | -12,193,000 |
| Dec 2023 | 250,000 | -12,845,000 | -12,300,000 | 14,052,000 | 2,739,000 | — | -11,133,000 |
| Dec 2022 | 0 | -15,311,000 | -14,260,000 | 15,763,000 | 3,284,000 | — | -13,360,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FENC | FENNEC PHARMACEUTICALS INC. | $311.24M | $8.96 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $299.16M | $1.20 | — |
| NMRA | Neumora Therapeutics, Inc. | $289.04M | $1.56 | — |
| ZURA | Zura Bio Ltd | $333.51M | $3.52 | — |
| SABS | SAB Biotherapeutics, Inc. | $279.86M | $3.66 | — |
News headlines (Yahoo Finance, 1h cache)
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
2026-06-11 12:45 · Yahoo
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
2026-06-09 12:45 · Yahoo
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
2026-05-27 13:00 · Yahoo
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
2026-05-21 21:51 · Yahoo
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
2026-05-21 21:39 · Yahoo
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
2026-05-18 04:49 · Yahoo
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn
2026-05-15 11:00 · Yahoo
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
2026-05-12 20:15 · Yahoo
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
2026-05-05 12:30 · Yahoo
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
2026-04-17 13:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.